Conjunctival Lymphoma

McGrath, Lindsay A, Ryan, David A, Warrier, Sunil K, Coupland, Sarah E ORCID: 0000-0002-1464-2069 and Glasson, William J (2023) Conjunctival Lymphoma. EYE, 37 (5). pp. 837-848.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1038/s41433-022-02176-2

Abstract

Lymphoma of the conjunctiva is an ocular malignancy derived from clonal proliferation of lymphocytes. The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL), follicular (FL), mantle cell (MCL) and T- cell subtypes are also seen. Clinical manifestations are non-specific, but include unilateral or bilateral painless salmon-pink conjunctival lesions. Approaches to treatment have centered around local immunomodulation, often with Interferon-α2b or Rituximab (anti-CD20 monoclonal antibody) with or without radiation. Although conjunctival lymphoma is generally considered an indolent disease, recent advances in next-generation sequencing have improved clinicians' ability to predict future recurrence or systemic disease through assessment of cytogenic and molecular features. In this paper, we review the classification, clinical features, diagnostic techniques, and emerging strategies for management and prognostication of conjunctival lymphomas.

Item Type:	Article
Uncontrolled Keywords:	Conjunctiva, Humans, Lymphoma, Eye Neoplasms, Conjunctival Neoplasms, Antineoplastic Agents, Lymphoma, B-Cell, Marginal Zone, Rituximab
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	18 Oct 2022 13:41
Last Modified:	02 Jun 2023 08:59
DOI:	10.1038/s41433-022-02176-2
Open Access URL:	https://www.nature.com/articles/s41433-022-02176-2
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3165598